These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 34597873)

  • 21. The role of drug resistance in poor viral suppression in rural South Africa: findings from a population-based study.
    Lippman SA; Mooney AC; Puren A; Hunt G; Grignon JS; Prach LM; Gilmore HJ; Truong HM; Barnhart S; Liegler T
    BMC Infect Dis; 2020 Mar; 20(1):248. PubMed ID: 32216752
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV reverse-transcriptase drug resistance mutations during early infection reveal greater transmission diversity than in envelope sequences.
    Lipscomb JT; Switzer WM; Li JF; Masciotra S; Owen SM; Johnson JA
    J Infect Dis; 2014 Dec; 210(11):1827-37. PubMed ID: 24924164
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Using machine learning and big data to explore the drug resistance landscape in HIV.
    Blassel L; Tostevin A; Villabona-Arenas CJ; Peeters M; Hué S; Gascuel O;
    PLoS Comput Biol; 2021 Aug; 17(8):e1008873. PubMed ID: 34437532
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trend of drug-resistant HIV type 1 emergence among therapy-naive patients in Nagoya, Japan: an 8-year surveillance from 1999 to 2006.
    Ibe S; Hattori J; Fujisaki S; Shigemi U; Fujisaki S; Shimizu K; Nakamura K; Kazumi T; Yokomaku Y; Mamiya N; Hamaguchi M; Kaneda T
    AIDS Res Hum Retroviruses; 2008 Jan; 24(1):7-14. PubMed ID: 18275342
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterizing the emergence and persistence of drug resistant mutations in HIV-1 subtype C infections using 454 ultra deep pyrosequencing.
    Bansode V; McCormack GP; Crampin AC; Ngwira B; Shrestha RK; French N; Glynn JR; Travers SA
    BMC Infect Dis; 2013 Jan; 13():52. PubMed ID: 23363532
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Promises and pitfalls of Illumina sequencing for HIV resistance genotyping.
    Brumme CJ; Poon AFY
    Virus Res; 2017 Jul; 239():97-105. PubMed ID: 27993623
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R and the effect of antiretroviral drug exposure on variant levels.
    Kozal MJ; Chiarella J; St John EP; Moreno EA; Simen BB; Arnold TE; Lataillade M
    Antivir Ther; 2011; 16(6):925-9. PubMed ID: 21900725
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV-1 diversity, transmission dynamics and primary drug resistance in Angola.
    Bártolo I; Zakovic S; Martin F; Palladino C; Carvalho P; Camacho R; Thamm S; Clemente S; Taveira N
    PLoS One; 2014; 9(12):e113626. PubMed ID: 25479241
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of Drug-Resistant Minority Variants in Untreated HIV-1-Infected Individuals With and Those Without Transmitted Drug Resistance Detected by Sanger Sequencing.
    Clutter DS; Zhou S; Varghese V; Rhee SY; Pinsky BA; Jeffrey Fessel W; Klein DB; Spielvogel E; Holmes SP; Hurley LB; Silverberg MJ; Swanstrom R; Shafer RW
    J Infect Dis; 2017 Aug; 216(3):387-391. PubMed ID: 28859436
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of drug resistance mutations in naïve and ART-treated patients infected with HIV-1 in Yaounde, Cameroon.
    Ceccarelli L; Salpini R; Moudourou S; Cento V; Santoro MM; Fokam J; Takou D; Nanfack A; Dori L; Torimiro J; Sarmati L; Andreoni M; Perno CF; Colizzi V; Cappelli G
    J Med Virol; 2012 May; 84(5):721-7. PubMed ID: 22431019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resistance to antiretroviral drugs in newly diagnosed, young treatment-naïve HIV-positive pregnant women in the province of KwaZulu-Natal, South Africa.
    Parboosing R; Naidoo A; Gordon M; Taylor M; Vella V
    J Med Virol; 2011 Sep; 83(9):1508-13. PubMed ID: 21739439
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low-Frequency Drug Resistance in HIV-Infected Ugandans on Antiretroviral Treatment Is Associated with Regimen Failure.
    Kyeyune F; Gibson RM; Nankya I; Venner C; Metha S; Akao J; Ndashimye E; Kityo CM; Salata RA; Mugyenyi P; Arts EJ; Quiñones-Mateu ME
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3380-97. PubMed ID: 27001818
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship between drug resistance mutations, plasma viremia, and CD4+ T-cell counts in patients with chronic HIV infection.
    de Mendoza C; Martín-Carbonero L; Gallego O; Corral A; González-Lahoz J; Soriano V
    J Med Virol; 2005 May; 76(1):1-6. PubMed ID: 15778973
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of Transmitted HIV-1 Drug Resistance Mutations Using Ultra- Deep Pyrosequencing in a Turkish Cohort.
    Sili U; Aksu B; Tekin A; Hasdemir U; Soyletir G; Korten V
    Curr HIV Res; 2018; 16(3):216-221. PubMed ID: 30198436
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of 454 Ultra-Deep Sequencing and Allele-Specific Real-Time PCR with Regard to the Detection of Emerging Drug-Resistant Minor HIV-1 Variants after Antiretroviral Prophylaxis for Vertical Transmission.
    Hauser A; Kuecherer C; Kunz A; Dabrowski PW; Radonić A; Nitsche A; Theuring S; Bannert N; Sewangi J; Mbezi P; Dugange F; Harms G; Meixenberger K
    PLoS One; 2015; 10(10):e0140809. PubMed ID: 26469189
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy.
    Peuchant O; Thiébaut R; Capdepont S; Lavignolle-Aurillac V; Neau D; Morlat P; Dabis F; Fleury H; Masquelier B;
    AIDS; 2008 Jul; 22(12):1417-23. PubMed ID: 18614864
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes.
    Simen BB; Simons JF; Hullsiek KH; Novak RM; Macarthur RD; Baxter JD; Huang C; Lubeski C; Turenchalk GS; Braverman MS; Desany B; Rothberg JM; Egholm M; Kozal MJ;
    J Infect Dis; 2009 Mar; 199(5):693-701. PubMed ID: 19210162
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low prevalence of transmitted genetic drug resistance in a cohort of HIV infected naïve patients entering antiretroviral treatment programs at two sites in northern South Africa.
    Nwobegahay J; Selabe G; Ndjeka NO; Manhaeve C; Bessong PO
    J Med Virol; 2012 Dec; 84(12):1839-43. PubMed ID: 23080485
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multimethod Longitudinal HIV Drug Resistance Analysis in Antiretroviral-Therapy-Naive Patients.
    Nanfack AJ; Redd AD; Bimela JS; Ncham G; Achem E; Banin AN; Kirkpatrick AR; Porcella SF; Agyingi LA; Meli J; Colizzi V; Nádas A; Gorny MK; Nyambi PN; Quinn TC; Duerr R
    J Clin Microbiol; 2017 Sep; 55(9):2785-2800. PubMed ID: 28659324
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.